Gilmore O'Neill, Editas Medicine CEO
July 27, 2022 11:04 AM EDTUpdated 04:22 PM
R&D

With Ver­tex and CRISPR some 30 pa­tients in, Ed­i­tas moves for­ward in sick­le cell pa­tients af­ter FDA lifts hold

Aayushi Pratap

News Reporter

With gene ther­a­pies for sick­le cell dis­ease prov­ing all the rage, one com­pa­ny is get­ting its FDA-im­posed chains re­moved.

Ed­i­tas Med­i­cine an­nounced Wednes­day that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times